advertisement
Bejanian M 15
Showing records 1 to 15 | Display only abstracts from Bejanian M in IGR 20-1106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Weinreb RN; Bacharach J; Brubaker JW; Medeiros FA; Bejanian M; Bernstein P; Robinson MR
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62 (IGR: 23-3)
90873 Phase 3, Randomized, 20-Month Study of Bimatoprost Implant in Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 1)
Medeiros FA; Walters TR; Kolko M; Coote M; Bejanian M; Goodkin ML; Guo Q; Zhang J; Robinson MR; Weinreb RN;
Ophthalmology 2020; 127: 1627-1641 (IGR: 21-4)
84829 24-Month Phase I/II Clinical Trial of Bimatoprost Sustained-Release Implant (Bimatoprost SR) in Glaucoma Patients
Craven ER; Walters T; Christie WC; Day DG; Lewis RA; Goodkin ML; Chen M; Wangsadipura V; Robinson MR; Bejanian M;
Drugs 2020; 80: 167-179 (IGR: 21-1)
79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Seal JR
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Weinreb RN; Liebmann JM
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)
79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Robinson MR; Burke J
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Cioffi GA; Goldberg I
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)
79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Bejanian M; Coote M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Brandt JD; Johnson CA
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)
79202 Intracameral Sustained-Release Bimatoprost Implant Delivers Bimatoprost to Target Tissues with Reduced Drug Exposure to Off-Target Tissues
Attar M
Journal of Ocular Pharmacology and Therapeutics 2019; 35: 50-57 (IGR: 20-1)
78514 Oral Memantine for the Treatment of Glaucoma: Design and Results of 2 Randomized, Placebo-Controlled, Phase 3 Studies
Zangwill LM; Schneider S; Badger H; Bejanian M
Ophthalmology 2018; 125: 1874-1885 (IGR: 20-1)
70828 Bimatoprost Sustained-Release Implants for Glaucoma Therapy: 6-Month Results from a Phase I/II Clinical Trial
Lewis RA; Christie WC; Day DG; Craven ER; Walters T; Bejanian M; Lee SS; Goodkin ML; Zhang J; Whitcup SM; Robinson MR;
American Journal of Ophthalmology 2017; 175: 137-147 (IGR: 18-2)
67185 Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon
Shen J; Bejanian M
Clinical Ophthalmology 2016; 10: 373-383 (IGR: 17-4)
56493 Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial
Goldberg I; Gil Pina R; Lanzagorta-Aresti A; Schiffman RM; Liu C; Bejanian M
British Journal of Ophthalmology 2014; 98: 926-931 (IGR: 16-1)
53875 Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial
Day DG; Walters TR; Schwartz GF; Mundorf TK; Liu C; Schiffman RM; Bejanian M
British Journal of Ophthalmology 2013; 97: 989-993 (IGR: 15-2)
